Skip to main content
Clinical Trials/NCT06287736
NCT06287736RecruitingNot Applicable

A Novel Neuromodulation Approach to Target Small Fiber Neuropathy Early in Diabetes and Measure Functional Recovery

Ohio State University2 sites in 1 country60 target enrollmentStarted: April 17, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
60
Locations
2
Primary Endpoint
Change in Pain level

Study Overview

Brief Summary

This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.

Detailed Description

Peripheral neuropathy (PN) is caused by diabetes, aging, chemotherapy, and over 30 other conditions, and impacts more than 30 million patients in the US alone. Diabetes is the number one cause of peripheral neuropathy, and more than half of patients with diabetes will eventually develop diabetic peripheral neuropathy (DPN), a complex set of symptoms including pain, numbness, tingling, and burning. Spinal cord stimulation (SCS) is an approved intervention for the treatment of chronic pain, including DPN. Spinal cord stimulation has had FDA approval for the treatment of painful DPN since 2015. This study is being done to learn more about the diagnosis of DPN and treatment of DPN with SCS.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Over 18 years old
  • Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic
  • Diagnosis of medically refractory pain secondary to diabetic neuropathy
  • Presence of pain for 12 months
  • Lower limb pain intensity score ≥4 on a visual analog scale
  • Pass pre-operative neuropsychological assessment (surgical group only)
  • Capable of providing informed consent

Exclusion Criteria

  • Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention
  • Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement
  • Coagulopathy that cannot be corrected
  • Unable to discontinue blood thinning medications
  • Hemoglobin A1c level greater than 10
  • Presence of systemic infection
  • Pregnancy

Arms & Interventions

Conventional Medical Management (CMM). Group1

No Intervention

Spinal Cord Stimulator (SCS) immediate activation. Group 2

Active Comparator

Intervention: Spinal Cord Stimulator Implantation (SCS) (Device)

Spinal Cord Stimulator (SCS) Delayed activation. Group 3

Active Comparator

Intervention: Spinal Cord Stimulator Implantation (SCS) (Device)

Outcomes

Primary Outcomes

Change in Pain level

Time Frame: 18 months post baseline

change in Visual analog pain scale (VAS). The VAS endpoints range from 'no pain at all' to 'pain as bad as it could be'

Change in Diabetic Peripheral Neuropathy (DPN) Pain using the Neuropathic pain diagnostic questionnaire (DN4)

Time Frame: 18 months post baseline

Neuropathic Pain Diagnostic "Douleur Neuropathique 4" questionnaire (DN4) is a screening questionnaire to help identify neuropathic pain (NP) in clinical practice and research. It is a clinican-administered questionnaire consisting of 10 items.The first 7 symptoms items are scored by interviewing the patient, and the 3 remaining items are scored by means of clinical examination. The scores are added and a score of 4 or more out of 10 is suggestive of neuropathic pain

Change in PROMIS quality of life in relation to pain level

Time Frame: 18 months post baseline

Change in patient-reported outcomes measurement (PROMIS 29)

Secondary Outcomes

  • change in neuropathic symptoms using Michigan Neuropathy Screening instrument(18 months post baseline)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Brian Dalm

Associate Professor, Neurological Surgery

Ohio State University

Study Sites (2)

Loading locations...

Similar Trials